Programmed cell death 1 (PD-1) Ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: A systematic review and meta-analysis

JCO Precision Oncology

Volumn 2017, Issue 1, 2017, Pages 1-15

  Khunger, Monica ^a   Hernandez, Adrian V ^b,c   Pasupuleti, Vinay ^d   Rakshit, Sagar ^a   Pennell, Nathan A ^e   Stevenson, James ^e   Mukhopadhyay, Sanjay ^a   Schalper, Kurt ^f   Velcheti, Vamsidhar ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; ARTICLE; DISEASE MARKER; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID MALIGNANT NEOPLASM; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 85032806849     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.16.00030     Document Type: Article

References (60)

1. Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982, 2015
2. Velcheti V, Schalper K: Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book 35:298-308, 2016
3. Velcheti V, Schalper KA, Carvajal DE, et al: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94:107-116, 2014
4. Brahmer JR: Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31: 1021-1028, 2013
5. National Comprehensive Cancer Network: NCCN collaborates with Bristol-Myers Squibb to study PD-L1 expression and test interpretation in lung cancer. https://www.nccn.org/about/news/newsinfo.aspx?NewsID=559
6. Hirsch F, McElhinny A, Stanforth D, et al: PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the Blueprint PD-L1 Assay Comparison Project. J Thorac Oncol 12:208-222, 2017
7. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6:e1000097, 2009
8. Higgins JP, Altman DG, Gøtzsche PC, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928, 2011
9. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997
10. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
11. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004-2012, 2015
12. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer.NEngl JMed 372: 2018-2028, 2015
13. Herbst RS, Soria J-C, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014
14. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123-135, 2015
15. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627-1639, 2015
16. Antonia S, Kim S, Spira A, et al: Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-näive patients with advanced non-small-cell lung cancer. J Clin Oncol 34, 2016 (suppl 15; abstr 9029)
17. Rizvi NA, Mazières J, Planchard D, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16:257-265, 2015
18. Verschraegen C, Chen F, Spigel D, et al: Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression. J Clin Oncol 34, 2016 (suppl; abstr 9036)
19. Herbst RS, Baas P, Kim D-W, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
20. Gettinger S, Rizvi NA, Chow LQ, et al: Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2980-2987, 2016
21. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-384, 2015
22. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 372:320-330, 2015
23. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
24. Hamid O, Sosman JA, Lawrence DP, et al: Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 31, 2013 (suppl; abstr 9010)
25. Hodi FS, Kluger H, Sznol M, et al: Long-term survival of ipilimumab-näive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial. Pigment Cell Melanoma Res 27:1199, 2014
26. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918, 2015
27. Daud AI, Wolchok JD, Robert C, et al: Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34:4102-4109, 2016
28. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma.NEngl JMed 372: 2521-2532, 2015
29. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
30. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33:1430-1437, 2015
31. Choueiri TK, Fishman MN, Escudier BJ, et al: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 32, 2014 (suppl 5s; abstr 5012)
32. McDermottDF, Sosman JA, Sznol M, et al: Atezolizumab, an anti-programmed death-ligand 1 antibody, inmetastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:833-842, 2016
33. Plimack E, Bellmunt J, Gupta S, et al: Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33, 2015 (suppl 15; abstr 4502)
34. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
35. Apolo AB, Infante JR, Hamid O, et al: Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase Ib trial. J Clin Oncol 34, 2016 (suppl 2S; abstr 367)
36. Massard C, Gordon MS, Sharma S, et al: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34: 3119-3125, 2016
37. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
38. Balar AV, Galsky MD, Rosenberg JE, et al: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 389:67-76, 2017
39. Sharma P, Callahan MK, Bono P, et al: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17:1590-1598, 2016
40. Segal N, Ou S, Balmanoukian A, et al: Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 33, 2015 (suppl; abstr 3011)
41. Ferris RL, Blumenschein G Jr, Fayette J, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867, 2016
42. Le DT, Bendell JC, Calvo E, et al: Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study J Clin Oncol 34, 2016 (suppl 4S; abstr 6)
43. Nishina T, Shitara K, Iwasa S, et al: Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 168)
44. Chung HC, Arkenau H-T, Wyrwicz L, et al: Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol 34, 2016 (suppl 4S; abstr 167)
45. Kaufman HL, Russell J, Hamid O, et al: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374-1385, 2016
46. Nghiem PT, Bhatia S, Lipson EJ, et al: PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:2542-2552, 2016
47. Antonia SJ, López-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883-895, 2016
48. Wakelee H, Patel JD, Heist R, et al: Phase II trial of atezolizumab for patients with PD-L1-selected advancedNSCLC (BIRCH): Updated efficacy and exploratory biomarker results: Topic: Medical oncology. J Thorac Oncol 11:S251, 2016 (suppl 11S; abstr ORAL01.04)
49. Rittmeyer A, Barlesi F, Waterkamp D, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017
50. Fehrenbacher L, Spira A, Ballinger M, et al: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387: 1837-1846, 2016
51. Spiegel DR, Chaft JE, Gettinger SN, et al: Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8028)
52. Carbognin L, Pilotto S, Milella M, et al: Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 10:e0130142, 2015
53. Aguiar PN Jr, Santoro IL, Tadokoro H, et al: The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy 8:479-488, 2016
54. Passiglia F, Bronte G, Bazan V, et al: PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis. Oncotarget 7:19738-19747, 2016
55. Wu P, Wu D, Li L, et al: PD-L1 and survival in solid tumors: A meta-analysis. PLoS One 10:e0131403, 2015
56. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218, 2013
57. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014
58. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
59. Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
60. Socinski M, Creelan B, Horn L, et al: NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol 27, 2016 (suppl 6; abstr LBA7)